Abstract
In a multicenter, multinational observational study that included neutropenic patients with bloodstream infections by extended-spectrum-β-lactamase-producing species, Gudiol et al. (Antimicrob. Agents Chemother. 61:e00164-17, 2017, https://doi.org/10.1128/AAC.00164-17) demonstrated that β-lactam/β-lactamase inhibitors are effective treatment options. A review of this work, however, reminds us that some lingering questions remain for specific high-risk subgroups.
Original language | English (US) |
---|---|
Article number | e01094 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 61 |
Issue number | 8 |
DOIs |
|
State | Published - Aug 2017 |
Keywords
- ESBL
- Gram negative
- MDRGN
- Meropenem
- Piperacillin-tazobactam
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases